HZNP News and Press, Horizon Therapeutics Public Limited Company From 08/24/23

2023-08-24 12:13:54 ET The Federal Trade Commission is likely to lose its effort to challenge Amgen's ( NASDAQ: AMGN ) planned $28 billion acquisition of Horizon Therapeutics ( NASDAQ: HZNP ), according to Oppenheimer, which cited legal experts. The memorandum of law fil...

2023-08-24 02:48:55 ET Summary Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. The number of holdings in the portfolio increased from 15 to 16. The top three stakes in the portfolio make up approximately 45% of the total. This article is par...

2023-08-23 11:27:44 ET More on Amgen Improved Outlook For Horizon Therapeutics And Amgen Amgen Is Back! Amgen Gives You Growth, Dividend Growth, And Value Amgen Inc. 2023 Q2 - Results - Earnings Call Presentation Horizon Therapeutics gains amid specul...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient groups who worked with Horizon also ranked the company first in 10 of the 14 ind...

2023-08-21 16:00:10 ET More on Horizon Therapeutics Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion? Improved Outlook For Horizon Therapeutics And Amgen H orizon Therapeutics, Activision among best bets for M&A deals to close 2023 sha...

2023-08-16 18:02:02 ET Summary Horizon Therapeutics accepted a bid of $116.50 per share to be acquired by Amgen in December last year - the deal value was $28.5bn in total. Horizon's drug products - led by Thyroid Eye Disease and gout therapies - earned $3.7bn last year. Amgen...

2023-08-16 14:31:30 ET Summary Horizon Therapeutics reports better-than-expected Q2 results, easing concerns about the Amgen acquisition failing to close due to Horizon's business underperformance. Net sales of Tepezza have been a key issue, but positive label changes and phase 4 ...

2023-08-13 09:24:10 ET Amgen's ( AMGN ) planned $28 billion purchase of Horizon Therapeutics ( NASDAQ: HZNP ) and Microsoft's $69 billion acquisition of video game giant Activision ( NASDAQ: ATVI ) are among the best bets for deals to close this year. Amgen ( AMGN ...

2023-08-08 07:05:32 ET Horizon Therapeutics press release ( NASDAQ: HZNP ): Q2 Non-GAAP EPS of $1.20 beats by $0.23 . Revenue of $945M (+7.8% Y/Y) beats by $71.49M . The company expects to advance its global expansion strategy, with multiple planned internation...

Second-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $445.5 ...